AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

12.280

-0.310-2.46%

Volume:504.70K

Turnover:6.21M

Market Cap:1.56B

PE:11.31

High:12.500

Open:12.320

Low:12.200

Close:12.590

Loading ...

Overview Company News Filings

These ASX 200 growth stocks could rise 30% to 100%

These ASX 200 growth shares could rise 65% and 100%

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Simply Wall St.

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Simply Wall St.

ASX Market Close: Strong jobs data dashes hopes of early rate cut | October 17, 2024

The Market Herald

Why AMP, Neuren, Ora Banda, and Paladin Energy shares are storming higher today

BRIEF-Neuren Pharmaceuticals Says Daybue Receives Marketing Authorization In Canada

Neuren Pharmaceuticals' Rett Syndrome Drug Secures Approval in Canada

MT Newswires Live

2 ASX 200 shares rising on big news

Neuren Pharmaceuticals Ltd - Daybue™ (Trofinetide) Receives Marketing Authorization in Canada

THOMSON REUTERS

Why Elixir Energy, Neuren, Reece, and TechnologyOne shares are tumbling today

ASX Market Update: Index rises as Rio Tinto eyes Arcadium Lithium in takeover bid | October 7, 2024

The Market Herald

Why Arcadium Lithium, Magellan, Neuren, and WA1 shares are storming higher today

Neuren Pharmaceuticals Gears Up for Phase 3 Trial of Genetic Disorder Drug Candidate; Shares Up 3%

MT Newswires Live

Guess which ASX 200 healthcare stock is charging higher following FDA update

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

The Market Herald

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NEU.AU/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":12.28,"timestamp":1741324320000,"preClose":12.59,"halted":0,"volume":504700,"delay":0,"changeRate":-0.024623,"change":-0.31,"floatShares":110014206,"shares":127012624,"eps":1.086099,"lyrEps":1.111713,"pbRate":4.29,"amount":6213731,"amplitude":0.023828,"volumeRatio":0.5927087081000431,"dividePrice":0,"prevYearClose":12.5,"fiveDayClose":13.23,"twentyDayClose":14.02},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":110014206,"roa":"34.05%","roe":"49.92%","lyrEps":1.111713,"volumeRatio":0.5927087081000431,"shares":127012624,"dividePrice":0,"high":12.5,"amplitude":0.023828,"preClose":12.59,"low":12.2,"week52Low":10.9,"pbRate":"4.29","psRate":"7.19","week52High":24,"institutionHeld":0,"latestPrice":12.28,"committee":-0.786738,"eps":1.086099,"divideRate":0,"volume":504700,"delay":0,"ttmEps":1.086099,"open":12.32,"prevYearClose":12.5,"prevWeekClose":13.23,"prevMonthClose":13.23,"prevQuarterClose":12.5,"fiveDayClose":13.23,"twentyDayClose":14.02,"sixtyDayClose":12.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:16,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2481763433","title":"These ASX 200 growth stocks could rise 30% to 100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481763433","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481763433?lang=en_us&edition=fundamental","pubTime":"2024-11-06 02:37","pubTimestamp":1730831820,"startTime":"0","endTime":"0","summary":"Are you on the hunt for big returns to supercharge your portfolio?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/06/these-asx-200-growth-stocks-could-rise-30-to-100/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7505","NEU.AU","BK7508","TWE.AU","BK7096","BK7097"],"gpt_icon":0},{"id":"2479442256","title":"These ASX 200 growth shares could rise 65% and 100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479442256","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479442256?lang=en_us&edition=fundamental","pubTime":"2024-10-30 03:33","pubTimestamp":1730230380,"startTime":"0","endTime":"0","summary":"Looking for big returns to supercharge your investment portfolio?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/30/these-asx-200-growth-shares-could-rise-65-and-100/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["NEU.AU","BK7508","BK7096","WEB.AU","BK7070"],"gpt_icon":0},{"id":"2478061427","title":"Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2478061427","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478061427?lang=en_us&edition=fundamental","pubTime":"2024-10-25 04:50","pubTimestamp":1729803020,"startTime":"0","endTime":"0","summary":"Key Insights Neuren Pharmaceuticals' estimated fair value is AU$15.24 based on 2 Stage Free Cash Flow to Equity Neuren...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/calculating-the-intrinsic-value-of-neuren-pharmaceuticals-li","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","NEU.AU","NEU","TV","DCF","BK4109","BK7096","BK4211","BK4100","FCF"],"gpt_icon":1},{"id":"2477387942","title":"Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2477387942","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477387942?lang=en_us&edition=fundamental","pubTime":"2024-10-22 12:41","pubTimestamp":1729572116,"startTime":"0","endTime":"0","summary":"For beginners, it can seem like a good idea  to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Neuren Pharmaceuticals . Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Neuren Pharmaceuticals with the means to add long-term value to shareholders.How Fast Is Neuren Pharmaceuticals Growing Its Earnings Per Share?Belief in the company remains high for insiders as there hasn't been a single share sold by the management or company board members. But ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-think-neuren-pharmaceuticals-044156322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NEU.AU","BK4109","BK7508","NEU","DCF","EBIT","BK7096"],"gpt_icon":0},{"id":"2476197765","title":"ASX Market Close: Strong jobs data dashes hopes of early rate cut | October 17, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2476197765","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476197765?lang=en_us&edition=fundamental","pubTime":"2024-10-17 14:28","pubTimestamp":1729146480,"startTime":"0","endTime":"0","summary":"The ASX200 closed up around 0.9% at 8,355 points after hitting a new record of 8,384 points just before September jobs data was released this morning.The better than expected unemployment rate of 4.1% saw markets reduce the odds of an RBA rate cut by years end from 1 in 2 to 1 in 3.Industrials was the strongest sector, up 1.85%, followed by Financials and Real Estate, both up 1.65%.IT was the biggest loser, down 1%, followed by Materials, down 0.4%.Neuren Pharmaceuticals  closed up 3% on news its Daybue product has been approved in Canada. This makes it the first and only drug approved in Canada for the treatment of Rett syndrome.Euro Manganese closed up 18.75% after proving reliability of its new demonstration plant with the facility running for five straight days.Koonenberry Gold  finished up 33.33% on news it’s set to transform into a gold and copper-gold explorer. The company will have a 4,410 square kilometre footprint across New South Wales.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-markets-close-strong-jobs-data-dashes-hopes-of-early-rate-cut-october-17-2024-2024-10-17/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["AW1.AU","EMN.AU","BK7096","BK7158","BK7508","NEU.AU","KNB.AU","BK7095","BK7091","BK7104","BK7061","BK7503","OFX.AU","APX.AU"],"gpt_icon":0},{"id":"2476135445","title":"Why AMP, Neuren, Ora Banda, and Paladin Energy shares are storming higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2476135445","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476135445?lang=en_us&edition=fundamental","pubTime":"2024-10-17 09:56","pubTimestamp":1729130175,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.7% to 8,345.3 points. Four ASX shares that are rising more","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/17/why-amp-neuren-ora-banda-and-paladin-energy-shares-are-storming-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IE00B7KXQ091.USD","LU0061475181.USD","GB00BDT5M118.USD","IE00BFSS7M15.SGD","LU0048584097.USD","IE00BJTD4V19.USD","IE00BWXC8680.SGD","BK4548","BK7083","LU0072462426.USD","PDN.AU","BK1229","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0011850046.USD","BK4554","LU0097036916.USD","LU0061474960.USD","BK4527","NEU.AU","IE0004445239.USD","BK4551","IE00BJTD4N35.SGD","IE00BJJMRY28.SGD","BK4566","OBM.AU","LU0080751232.USD","IE00B775SV38.USD","XJO.AU","00495","IE00BKDWB100.SGD","BK4535","IE00B19Z8X17.USD","IE00B1XK9C88.USD","BK1258","IE00B19Z8W00.USD","IE00B19Z9505.USD","AMP.AU","BK7104","BK7096","BK7509","BK7508","BK4588","BK4579","IE00BJLML261.HKD","BK4559","AMP","LU0061474705.USD","IE00BFSS8Q28.SGD"],"gpt_icon":0},{"id":"2476182134","title":"BRIEF-Neuren Pharmaceuticals Says Daybue Receives Marketing Authorization In Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2476182134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476182134?lang=en_us&edition=fundamental","pubTime":"2024-10-17 09:28","pubTimestamp":1729128498,"startTime":"0","endTime":"0","summary":"Oct 17 (Reuters) - Neuren Pharmaceuticals Ltd   :   * DAYBUE (TROFINETIDE) RECEIVES MARKETING AUTHORIZATION IN CANADA Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2476189923","title":"Neuren Pharmaceuticals' Rett Syndrome Drug Secures Approval in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2476189923","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476189923?lang=en_us&edition=fundamental","pubTime":"2024-10-17 08:57","pubTimestamp":1729126669,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said its partner, Nasdaq-listed Acadia Pharmaceuticals, secured marketing authorization from Health Canada for its Daybue drug developed to treat Rett syndrome in adult and pediatric patients aged two and older, according to a Thursday filing with the Australian Securities Exchange.Rett syndrome is a genetic neurological disorder causing progressive motor skills and language loss.The approval was the first received outside the US, said Neuren Chief Executive Jon Pilcher.Neuren Pharmaceuticals shares rose more than 2% in morning trade on Thursday.Price : $12.99, Change: $+0.29, Percent Change: +2.28%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","AUD","BK4125","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2476907027","title":"2 ASX 200 shares rising on big news","url":"https://stock-news.laohu8.com/highlight/detail?id=2476907027","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476907027?lang=en_us&edition=fundamental","pubTime":"2024-10-17 07:45","pubTimestamp":1729122341,"startTime":"0","endTime":"0","summary":"The Australian share market is rebounding nicely on Thursday following a solid session on Wall Street overnight. Two ASX 200 shares that are contributing are listed below. Here's why they are pushing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/17/2-asx-200-shares-rising-on-big-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","LU2065171311.SGD","BK7508","BK4139","LU2065169927.USD","LU2065170008.USD","LU2065171402.SGD","ACAD","NXT.AU","BK7043","BK7503","NEU.AU"],"gpt_icon":0},{"id":"2476905751","title":"Neuren Pharmaceuticals Ltd - Daybue™ (Trofinetide) Receives Marketing Authorization in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2476905751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476905751?lang=en_us&edition=fundamental","pubTime":"2024-10-17 06:32","pubTimestamp":1729117976,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241016:nFWN3LS1FI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2473450699","title":"Why Elixir Energy, Neuren, Reece, and TechnologyOne shares are tumbling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2473450699","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473450699?lang=en_us&edition=fundamental","pubTime":"2024-10-08 09:33","pubTimestamp":1728351237,"startTime":"0","endTime":"0","summary":"] However, given TNE is now trading in line with high quality ASX TMT peers and GSe/VA Consensus are already sitting above FY24E PBT guidance , risk-reward appears fair with balanced risks to both the upside and downside.\"","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/08/why-elixir-energy-neuren-reece-and-technologyone-shares-are-tumbling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["REH.AU","BK7508","NEU.AU","BK7016","EXR.AU","XJO.AU","BK7096","BK7031","BK7142","BK7503","TNE.AU"],"gpt_icon":0},{"id":"2473145180","title":"ASX Market Update: Index rises as Rio Tinto eyes Arcadium Lithium in takeover bid | October 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2473145180","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473145180?lang=en_us&edition=fundamental","pubTime":"2024-10-07 11:32","pubTimestamp":1728271920,"startTime":"0","endTime":"0","summary":"The ASX200 has been up around 0.6% of a percent at 8,198 points in early afternoon trade.The labour day holiday in some states has seen the bourse trading in lower volumes, as investors continue to digest the unfolding conflict in the Middle East.The sectors are a mixed bag, and both Financials and IT have been leading the market higher – both up 1.35%, followed by Materials up 0.65%.Mining giant Rio Tinto  has been down 1.5% on news it has made a takeover approach to Arcadium Lithium . Rio has confirmed the potential acquisition, but has underscored there is no guarantee the takeover will go ahead. The company says it will update the market when appropriate.Rio has been trading at $122.05 and Arcadium Lithium has been up 43% at $6.00.Evolution Mining  has been down around 2% after broker Jefferies downgraded the gold miner to a hold rating. However, the broker lifted its price target by 6.4% to $5.00 amid broad weakness in the gold sector.Neuren Pharmaceuticals has been up 2.3% after ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-index-rises-as-rio-tinto-eyes-arcadium-lithium-in-takeover-bid-october-7-2024-2024-10-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["NEU.AU","BK7095","BK7104","BK7508","LTM.AU","BK4109","BK7507","BK7506","EVN.AU","PLS.AU","BK7511","RIO.AU","BK7096","BK4144","BK7504","BK7036","ALTM"],"gpt_icon":0},{"id":"2473119721","title":"Why Arcadium Lithium, Magellan, Neuren, and WA1 shares are storming higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2473119721","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473119721?lang=en_us&edition=fundamental","pubTime":"2024-10-07 09:25","pubTimestamp":1728264354,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.5% to 8,188.4 points. Four ASX shares that are rising more","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/07/why-arcadium-lithium-magellan-neuren-and-wa1-shares-are-storming-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4144","BK4109","BK7096","MFG.AU","PLS.AU","ALTM","XJO.AU","BK7062","BK7504","BK7507","LTM.AU","BK7036","BK7095","RIO.AU","BK7508","BK7511","NEU.AU","WA1.AU"],"gpt_icon":0},{"id":"2473511614","title":"Neuren Pharmaceuticals Gears Up for Phase 3 Trial of Genetic Disorder Drug Candidate; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2473511614","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473511614?lang=en_us&edition=fundamental","pubTime":"2024-10-07 08:56","pubTimestamp":1728262597,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  is advancing preparations for a phase 3 trial of its drug candidate NNZ-2591 in children with Phelan-McDermid syndrome, according to a Monday filing with the Australian Securities Exchange.The Phelan-McDermid syndrome is a rare genetic disorder characterized by the loss or structural change in a portion of chromosome 22.The announcement follows a meeting with the US Food and Drug Administration in which the company and the US FDA reached alignment on key aspects of the program, with the company submitting additional information to confirm endpoints for the primary efficacy assessmentThe 13-week program is a single randomized, double-blind, placebo-controlled trial, the filing said.Shares rose almost 3% in recent Monday trade.Price : $14.43, Change: $+0.38, Percent Change: +2.70%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4125","NEU.AU","BK7096","BK4121","GENE","AUD","BK7508"],"gpt_icon":0},{"id":"2473113482","title":"Guess which ASX 200 healthcare stock is charging higher following FDA update","url":"https://stock-news.laohu8.com/highlight/detail?id=2473113482","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473113482?lang=en_us&edition=fundamental","pubTime":"2024-10-07 07:51","pubTimestamp":1728258688,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Ltd  shares are having a strong start to the week. In morning trade, the ASX 200 healthcare stock is up over 4% to $14.63. Why is this ASX 200 healthcare stock charging higher?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/07/guess-which-asx-200-healthcare-stock-is-charging-higher-following-fda-update/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2473119507","title":"Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2473119507","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473119507?lang=en_us&edition=fundamental","pubTime":"2024-10-07 07:33","pubTimestamp":1728257580,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  has said it’s received a “positive” response from the FDA regarding a potential approval for its Phase 3 trial to treat children with Phelan-McDermid Syndrome . Using Neuren’s in-house drug candidate of interest, NNZ-2591, the company and the FDA have agreed a Phase 3 trial would be a single randomised double-blind and placebo-controlled 13 week trial looking at children aged 3-12 presenting with PMS.The company believes its current plans for Phase 3 testing would be more streamline than Phase 2 with a “less burdensome safety monitoring plan” appearing to be acceptable for the FDA.To that end, the company is currently preparing for Phase 3 trials with service providers and trial sites being identified.Its drug of interest, NNZ-2591, has reportedly unlocked repeated success in mice trials.“There are no medications, drugs, or therapies specifically for PMS, which has an overwhelming unmet medical need,” Neuren wrote on Monday.Join the discussion: See what HotCoppe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/neuren-sees-fda-greenlight-for-3rd-trial-into-children-with-phelan-mcdermid-syndrome-2024-10-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0}],"pageSize":16,"totalPage":7,"pageCount":6,"totalSize":106}]}}